Investigating the effects of Ocrevus on cognitive fatigue in multiple sclerosis
A Biomarker for Cognitive Fatigue Using Functional Imaging in MS
This study is testing how the medication Ocrevus affects cognitive fatigue in people with relapsing-remitting multiple sclerosis to see if it helps them think better during challenging tasks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 64 Years |
| Sex | All |
| Sponsor | Kessler Foundation Academic / other |
| Locations | 1 site (West Orange, New Jersey) |
| Trial ID | NCT04448977 on ClinicalTrials.gov |
What this trial studies
This research examines how the disease-modifying medication Ocrevus affects cognitive fatigue in individuals with relapsing-remitting multiple sclerosis (RRMS). The study utilizes functional MRI (fMRI) to assess changes in brain activity related to cognitive fatigue during demanding tasks. Participants will include those newly prescribed Ocrevus or Copaxone, as well as healthy volunteers. The research aims to understand how cognitive fatigue evolves with treatment duration and its impact on specific brain regions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-64 with relapsing-remitting multiple sclerosis who have been newly prescribed a disease-modifying medication.
Not a fit: Patients with significant neurological events, psychiatric illnesses, or those unable to undergo MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for cognitive fatigue in patients with multiple sclerosis.
How similar studies have performed: Other studies have explored cognitive fatigue in multiple sclerosis, but this specific investigation into Ocrevus's effects is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18-64. * Relapsing remitting multiple sclerosis * Been newly prescribed a new disease modifying medication for MS (either Ocrevus or Copaxone) * or healthy volunteer who can speak English fluently. Exclusion Criteria: * History of head injury, stroke, seizures, or any other significant neurological event other than MS * Flare up of MS symptoms within the past month. * History of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder. * Pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments. * left handed. * Not able to have an MRI
Where this trial is running
West Orange, New Jersey
- Kessler Foundation — West Orange, New Jersey, United States (Recruiting)
Study contacts
- Principal investigator: John DeLuca, PhD — Kessler Foundation
- Study coordinator: Nancy Moore, M.A.
- Email: nbmoore@kesslerfoundation.org
- Phone: 973-324-8450
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.